Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

SELECTED QUARTERLY FINANCIAL DATA

SELECTED QUARTERLY FINANCIAL DATA

12 Months Ended

Dec. 31, 2013

12. SELECTED QUARTERLY FINANCIAL DATA

	Year Ended December 31, 2013												Year Ended December 31, 2012

	Q1			Q2			Q3			Q4			Q1			Q2			Q3			Q4
	(unaudited, in thousands, except per share amounts)
Revenue	$	—		$	1,400		$	—		$	5,750		$	750		$	1,500		$	—		$	—
Net loss	$	(25,574	)	$	(22,768	)	$	(23,824	)	$	(16,861	)	$	(23,174	)	$	(24,738	)	$	(25,456	)	$	(25,472	)
Net loss per share, basic and diluted	$	(0.29	)	$	(0.26	)	$	(0.27	)	$	(0.19	)	$	(0.32	)	$	(0.35	)	$	(0.36	)	$	(0.30	)
Weighted average shares used in computing net loss per share, basic and diluted		87,141			87,147			87,430			87,430			71,422			71,458			71,636			85,274

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References + Details